Diacerein
From Wikipedia, the free encyclopedia
 |
|
|
Diacerein
|
|
| Systematic (IUPAC) name | |
| 4,5-diacetyloxy-9,10-dioxo-anthracene-2- carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| Chemical data | |
| Formula | C19H12O8 |
| Mol. mass | 368.294 g/mol |
| Synonyms | Diacetylrhein, diacerhein |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | Hepatic: deacetylation to rhein, later glucuronidation and sulfate conjugation |
| Half life | 4 to 5 hours |
| Excretion | Renal (30%) |
| Therapeutic considerations | |
| Pregnancy cat. |
Lacking information |
| Legal status | |
| Routes | Oral |
Diacerein (INN), also known as diacetylrhein, is a drug used in the treatment of osteoarthritis. It works by inhibiting interleukin-1.
A 2005 Cochrane review found diacerein to be slightly, but significantly, more effective than placebo in controlling the pain of osteoarthritis.[1]
[edit] Side effects
The most common side effects of diacerein treatment are gastrointestinal, such as diarrhea.[1][2]
[edit] References
- ^ a b Fidelix TS, Soares BG, Trevisani VF (2006). "Diacerein for osteoarthritis". Cochrane database of systematic reviews (Online) (1): CD005117. doi:. PMID 16437519. Free summary
- ^ (French) Diacereine. BIAM (March 24, 1999). Retrieved on 2007-06-13.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
